One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial

AIM: The aim of this study was to compare the efficacy and safety of once-daily human glucagon-like peptide-1 analogue liraglutide with dipeptidyl peptidase-4 inhibitor sitagliptin, each added to metformin, over 52 weeks in individuals with type 2 diabetes. METHODS: In an open-label, parallel-group...

Descripción completa

Detalles Bibliográficos
Autores principales: Pratley, R, Nauck, M, Bailey, T, Montanya, E, Cuddihy, R, Filetti, S, Garber, A, Thomsen, A B, Hartvig, H, Davies, M
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2011
Materias:
Diabetes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085127/
https://www.ncbi.nlm.nih.gov/pubmed/21355967
http://dx.doi.org/10.1111/j.1742-1241.2011.02656.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085127/
https://www.ncbi.nlm.nih.gov/pubmed/21355967
http://dx.doi.org/10.1111/j.1742-1241.2011.02656.x

Ejemplares similares